Ufuk Abacioglu

Ufuk Abacioglu

Auto-generated profile, based on publicly available information

Ufuk Abacioglu

Marmara University Hospital, Istanbul, Turkey

Research Focus & Metrics

Academic Career Length

31Years (1996-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 January 2011 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
MKMartin Kocher
Martin Kocher
Riccardo SoffiettiRiccardo Soffietti
Riccardo Soffietti
UAUfuk Abacioglu
Ufuk Abacioglu
SFSalvador Villà Freixa
Salvador Villà Freixa
FFFrancois Fauchon
Francois Fauchon
RMRolf-Peter Mueller
Rolf-Peter Mueller
Purpose: This European Organisation for Research and Treatment of Cancer phase III trial assesses whether adjuvant whole-brain radiotherapy (WBRT) increases the duration of functional independence after surgery or radiosurgery of brain metastases.Patients and Methods: Patients with one to three brain metastases of solid tumors (small-cell lung cancer excluded) with stable systemic disease or asymptomatic primary tumors and WHO performance status (PS) of 0 to 2 were treated with complete surgery or radiosurgery and randomly assigned to adjuvant WBRT (30 Gy in 10 fractions) or observation (OBS). The primary end point was time to WHO PS deterioration to more than 2.Results: Of 359 patients, 199 underwent radiosurgery, and 160 underwent surgery. In the radiosurgery group, 100 patients were allocated to OBS, and 99 were allocated to WBRT. After surgery, 79 patients were allocated to OBS, and 81 were allocated to adjuvant WBRT. The median time to WHO PS more than 2 was 10.0 months (95% CI, 8.1 to 11.7 months) after OBS and 9.5 months (95% CI, 7.8 to 11.9 months) after WBRT (P = .71). Overall survival was similar in the WBRT and OBS arms (median, 10.9 v 10.7 months, respectively; P = .89). WBRT reduced the 2-year relapse rate both at initial sites (surgery: 59% to 27%, P < .001; radiosurgery: 31% to 19%, P = .040) and at new sites (surgery: 42% to 23%, P = .008; radiosurgery: 48% to 33%, P = .023). Salvage therapies were used more frequently after OBS than after WBRT. Intracranial progression caused death in 78 (44%) of 179 patients in the OBS arm and in 50 (28%) of 180 patients in the WBRT arm.Conclusion: After radiosurgery or surgery of a limited number of brain metastases, adjuvant WBRT reduces intracranial relapses and neurologic deaths but fails to improve the duration of functional independence and overall survival.

1 September 2012 in The Lancet Oncology
Verified
Journal Article
Closed access
AMAnnika Malmström
Annika Malmström
BGBjørn Grønberg
Bjørn Grønberg
CMChristine Marosi
Christine Marosi
RSRoger Stupp
Roger Stupp
DFDidier Frappaz
Didier Frappaz
RHRoger Henriksson
Roger Henriksson

1 January 2013 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
Riccardo SoffiettiRiccardo Soffietti
Riccardo Soffietti
MKMartin Kocher
Martin Kocher
UAUfuk M. Abacioglu
Ufuk M. Abacioglu
SFSalvador Villà Freixa
Salvador Villà Freixa
FFFrançois Fauchon
François Fauchon
ABAndrew Bottomley
Andrew Bottomley
Purpose: This phase III trial compared adjuvant whole-brain radiotherapy (WBRT) with observation after either surgery or radiosurgery of a limited number of brain metastases in patients with stable solid tumors. Here, we report the health-related quality-of-life (HRQOL) results. Patients and Methods: HRQOL was a secondary end point in the trial. HRQOL was assessed at baseline, at 8 weeks, and then every 3 months for 3 years with the European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire C30 and Brain Cancer Module. The following six primary HRQOL scales were considered: global health status; physical, cognitive, role, and emotional functioning; and fatigue. Statistical significance required P ≤ .05, and clinical relevance required a ≥ 10-point difference. Results: Compliance was 88.3% at baseline and dropped to 45.0% at 1 year; thus, only the first year was analyzed. Overall, patients in the observation only arm reported better HRQOL scores than did patients who received WBRT. The differences were statistically significant and clinically relevant mostly during the early follow-up period (for global health status at 9 months, physical functioning at 8 weeks, cognitive functioning at 12 months, and fatigue at 8 weeks). Exploratory analysis of all other HRQOL scales suggested worse scores for the WBRT group, but none was clinically relevant. Conclusion: This study shows that adjuvant WBRT after surgery or radiosurgery of a limited number of brain metastases from solid tumors may negatively impact some aspects of HRQOL, even if these effects are transitory. Consequently, observation with close monitoring with magnetic resonance imaging (as done in the EORTC trial) is not detrimental for HRQOL.

1 August 2006 in The Lancet Oncology
Verified
Journal Article
Closed access
AOAurelius Omlin
Aurelius Omlin
MAMaurizio Amichetti
Maurizio Amichetti
DADavid Azria
David Azria
BCBernard F Cole
Bernard F Cole
PFPhilippe Fourneret
Philippe Fourneret
GGGuenther Gruber
Guenther Gruber

1 November 2002 in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
Verified
Journal Article
Closed access
UAUfuk Abacioglu
Ufuk Abacioglu
OUOmer Uzel
Omer Uzel
MSMeric Sengoz
Meric Sengoz
STSedat Turkan
Sedat Turkan
AOAhmet Ober
Ahmet Ober

1 October 2006 in Radiotherapy and Oncology
Verified
Journal Article
Closed access
EOEnis Ozyar
Enis Ozyar
USUgur Selek
Ugur Selek
SLSiddihartha Laskar
Siddihartha Laskar
OUOmer Uzel
Omer Uzel
YAYavuz Anacak
Yavuz Anacak
IAIbtisam Lale Atahan
Ibtisam Lale Atahan